

Figure S1. 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment affects histone modification levels in NLRP3 and Nrf2 promoters in DOX-induced cardiomyopathy. The DNA gels of different histone modifications in the (A) NLRP3 and (B) Nrf2 promoter regions in AC16 cells after treating with DOX or DOX + 1,25(OH)<sub>2</sub>D<sub>3</sub>. NLRP3, nod-like receptor family pyrin domain containing 3; Nrf2, nuclear erythroid 2-related factor 2; DOX, doxorubicin hydrochloride.

